CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock ...

CRISPR Therapeutics (CRSP) recently showcased new preclinical results for its CTX460 therapy, revealing strong gene and mRNA correction in animal models for Alpha-1 Antitrypsin Deficiency. The ...

CRISPR Therapeutics CRSP and Intellia Therapeutics NTLA are leading developers of therapies that utilize the Nobel Prize-winning CRISPR/Cas9 gene editing technology. While CRSP is the first and only ...

Recent discussions on X about CRISPR Therapeutics (CRSP) have been buzzing with excitement following the company's stock hitting a 52-week high of $62.32 and news of a significant insider purchase by ...

Shares of CRISPR Therapeutics (NASDAQ:CRSP) continued to drop in the premarket on Tuesday after the Swiss biotech posted lower-than-expected Q2 2025 financials, as investors focused on sales from its ...

Attempting to cash in on what's likely to be a relatively short-lived mania isn't a good idea for most investors most of the ...